Phase II Doubleblind Exploratory Study of GSK2402968 in Ambulant Subjects With Duchenne Muscular Dystrophy
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether GSK2402968 given as a continuous dose and
as an intermittent dose is effective and safe in the treatment of Duchenne muscular
dystrophy.